The phase II TACTI-002 trial (NCT03625323) evaluated eftilagimod alpha (LAG-3 agonist) in combination with pembrolizumab in two cohorts of NSCLC patients—PD-X naïve (no prior systemic therapy) and PD-X refractory (progressed after prior PD-1/L1 therapy). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.